Clinical trial Recruiting at 2 sites Phase 4 Interventional Ages 18 and up

Remifentanil versus rocuronium to improve video-laryngoscope intubation conditions

Official title: Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation in Patients Undergoing General Anaesthesia - a Multicentre Randomised Controlled Trial -The ROCVIDEO Trial

Run by Nordsjaellands Hospital · NCT06564857 · Data updated 2026-11-12

This trial will see if a large dose of remifentanil can replace rocuronium to make video-laryngoscope intubation easier and safer for adults having general anaesthesia.

More Tracheal Intubation trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment2684 (estimated)
SponsorNordsjaellands Hospital
Academic / other
Locations2 sites (Copenhagen and 1 other locations)
StatusRecruiting
StartedNovember 17, 2025
Main results expectedApril 1, 2027
Study endsApril 8, 2027
Registry record updatedSeptember 21, 2026
Trial IDNCT06564857 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older scheduled for general anaesthesia with orotracheal intubation who are ASA class I–III and not indicated for rapid sequence induction are eligible.

Probably not a fit

Patients needing rapid sequence induction, those with neuromuscular disease or contraindications to remifentanil or rocuronium, pregnant or breastfeeding patients, or those having oral/pharyngeal/laryngeal surgery are unlikely to benefit from joining this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 4, randomized interventional comparison of remifentanil versus the neuromuscular blocker rocuronium during induction for orotracheal intubation using video laryngoscopy. Adult patients (ASA I–III) undergoing general anaesthesia who do not require rapid sequence induction are enrolled and randomized to receive either remifentanil-based induction or rocuronium before intubation. The trial will record intubation conditions, airway complications, and perioperative respiratory or neuromuscular adverse events. The study is conducted at North Zealand Hospital (Hillerød) and Rigshospitalet (Copenhagen) in Denmark with standard anesthesia monitoring and informed consent procedures.

Why it matters

Potential benefit: If successful, this could allow safe intubation without neuromuscular blockers, reducing the risk of residual paralysis, anaphylaxis, and some postoperative pulmonary complications.

How similar studies have gone: Previous studies have tested high-dose opioids as an alternative to neuromuscular blockers with mixed results, so this trial adds head-to-head comparative data rather than introducing a completely novel idea.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults ≥ 18 years
* Undergoing general anaesthesia requiring oro-tracheal intubation
* Absence of indication for rapid sequence induction
* American Society of Anesthesiologists (ASA) physical status score I - III

Exclusion Criteria:

* Known allergies or contraindications to rocuronium (e.g. neuromuscular disease) or remifentanil
* Awake intubation
* Double-lumen endotracheal tube
* Oral, pharyngeal, and laryngeal surgery
* Surgical contraindication for NMBAs (e.g. use of nerve stimulator)
* Patients who are pregnant or breastfeeding
* Patients who do not understand Danish or are unable to give informed consent

Where it's running

  • Department of Anesthesiology, NOH, Rigshospitalet
    Copenhagen, Denmark
    Recruiting
  • Department of Anesthesiology, North Zeeland Hospital
    Hillerød, Denmark
    Recruiting

Study contacts

  • Principal investigator: Anders K Nørskov, PhD — Department of Anaesthesia, Nordsjællands Hospital - Hillerød, Denmark
  • Study coordinator: Anders K Nørskov, PhD
  • Email: anders.kehlet.noerskov@regionh.dk
  • Phone: 48292510

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.